A New PET Tracer Makes Meningiomas Stand Out Against the Brain’s Near-Silent Background

A new radioactive imaging agent has produced exceptionally high-contrast pictures of meningiomas, the most common primary tumors arising from the membranes surrounding the brain and spinal cord. In a retrospective study of 37 patients, scans made with the fluorine-18-labeled compound [¹⁸F]SiTATE identified 69 lesions and revealed them as intensely bright against brain tissue that showed almost no tracer activity. The findings suggest that the technique could give clinicians a sharper map of meningiomas than conventional anatomical imaging alone, potentially helping them distinguish tumor from normal tissue, plan treatment and monitor disease. The study, conducted by researchers in Greece and Cyprus, evaluated both suspected and previously diagnosed meningiomas using positron emission tomography combined with computed tomography, or PET/CT. Although the results do not yet establish that [¹⁸F]SiTATE is superior to existing tracers, the striking tumor-to-background contrast is likely to attract attention in a field increasingly interested in molecular imaging and precision treatment.

Meningiomas develop from the meninges, thin protective layers that wrap the central nervous system. Many grow slowly and cause no symptoms, while others press on the brain, nerves or blood vessels and produce seizures, headaches, visual problems or neurological impairment. Magnetic resonance imaging is the standard tool for locating and characterizing these tumors, but MRI primarily shows anatomy: the shape, size and position of a mass. It does not directly reveal the molecular features that distinguish meningioma cells from nearby structures. That distinction can become difficult when tumors lie close to bone, scar tissue, the orbit or critical brain regions, or when doctors need to determine whether residual tissue after surgery represents tumor or postoperative change. Somatostatin receptor-targeted PET offers a different approach by exploiting a biological signature. Many meningiomas express somatostatin receptor subtype 2, or SSTR2, on their cell surfaces. A radiolabeled molecule designed to bind that receptor can act as a molecular beacon, concentrating in receptor-rich tumor tissue and allowing the PET scanner to display its distribution.

The tracer used in the study belongs to a newer generation of fluorine-18 compounds designed to target somatostatin receptors. PET does not photograph a tumor directly. Instead, it detects pairs of gamma rays produced when the radioactive isotope fluorine-18 undergoes positron decay. The emitted positron travels a short distance through tissue before colliding with an electron, generating two photons that fly in nearly opposite directions. The scanner detects these coincident photons and reconstructs their origin in three dimensions. [¹⁸F]SiTATE combines this physical signal with biological targeting: its peptide component recognizes somatostatin receptors, while fluorine-18 provides the radioactive label. The CT component supplies anatomical landmarks and helps correct the PET signal for tissue attenuation. Compared with gallium-68-labeled tracers, which are already widely used for SSTR imaging, fluorine-18 may offer practical advantages, including a longer physical half-life of approximately 110 minutes. That can support broader distribution from a central radiopharmacy, more flexible scheduling and potentially higher-resolution imaging because fluorine-18 emits lower-energy positrons that travel a shorter distance before annihilation.

Sachpekidis and colleagues retrospectively examined 37 consecutive [¹⁸F]SiTATE PET/CT examinations performed in patients with suspected or known meningioma. The investigators assessed whether lesions could be detected, how much tracer they absorbed and how strongly they contrasted with normal tissues and other lesions. Where available, PET findings were checked against histopathology, the microscopic examination of tissue removed during surgery or biopsy. When pathology was not available, the researchers used MRI follow-up as part of a composite reference standard. This design reflects the realities of clinical imaging, where not every suspected or stable meningioma is surgically sampled, but it also limits the certainty with which PET results can be judged. A retrospective cohort can reveal promising patterns, yet it cannot eliminate selection bias or determine how the method performs in a prospectively assembled, representative patient population.

The headline result was that focal tracer uptake consistent with meningioma appeared in 32 of the 37 examinations, equivalent to 86.5 percent. Across those positive examinations, the scans identified 69 lesions in total. The tumors showed a mean maximum standardized uptake value, or SUVmax, of 20.44 with a standard deviation of 14.54. SUVmax is a semiquantitative measure of radioactivity concentration normalized to the injected dose and the patient’s body characteristics; it is commonly used as an approximate indicator of tracer accumulation. The mean SUVpeak, which averages uptake within a small, standardized, high-activity region rather than relying on a single hottest voxel, was 12.10 with a standard deviation of 8.04. Both measures indicated intense uptake. The researchers reported that meningiomas accumulated significantly more [¹⁸F]SiTATE than non-meningioma lesions and reference tissues, with p values below 0.01 in all comparisons except the pituitary gland. That exception is biologically unsurprising: the pituitary naturally expresses somatostatin receptors and can therefore show physiological tracer activity.

The contrast was particularly dramatic because normal brain parenchyma absorbed very little of the tracer. Its mean SUVmax was only 0.11 with a standard deviation of 0.06. In practical terms, the tumor signal was not merely strong; it was set against a remarkably quiet background. Such contrast matters because PET interpretation depends on the difference between a target and its surroundings. A lesion with moderate uptake can still be conspicuous if adjacent tissue is inactive, while even high uptake may be difficult to interpret when normal structures are equally bright. The low brain background could make meningiomas easier to outline, particularly at the margins where MRI may show complex relationships with the dura, bone or cortex. It may also help identify multiple lesions, including small deposits that are less obvious on routine anatomical scans. However, high contrast does not automatically mean perfect sensitivity. Five examinations did not show focal uptake considered consistent with meningioma, and the supplied results do not specify whether those cases represented false-negative scans, lesions with low receptor expression, technical limitations or alternative diagnoses.

Beyond simple detection, the study calculated measures intended to describe the total molecular burden of receptor-expressing tumor. The somatostatin receptor-expressing tumor volume, or SRETV, averaged 9.81 milliliters with a standard deviation of 13.64. This parameter estimates the volume of tissue that exceeds a defined uptake threshold, rather than merely recording the dimensions of a lesion on MRI. The investigators also reported total lesion somatostatin receptor expression, or TLSRE, with a mean of 102.86 and a standard deviation of 193.69. TLSRE integrates lesion volume and tracer uptake, providing a composite estimate of how much receptor-targeted signal is present across the tumor burden. These measurements could eventually help compare patients, follow changes over time or select candidates for radionuclide therapy, in which a therapeutic radioactive payload is attached to a receptor-binding molecule. Yet the wide variation around the means shows that uptake differed substantially between patients. The study was designed to evaluate feasibility and imaging characteristics, not to prove that SRETV or TLSRE predicts growth, treatment response or survival.

The absence of tracer-related adverse events in the 37 examinations is another encouraging observation, although it should be interpreted cautiously. A small retrospective cohort can identify obvious short-term safety signals but cannot establish uncommon risks or fully characterize tolerability. The researchers also reported no external funding or grants for the work and declared no competing financial interests related to the study; one author, Christos Sachpekidis, is an associate editor of the journal. All participants provided informed consent, and the procedures were reported to comply with relevant ethical standards and the Declaration of Helsinki. The article’s data are available from the corresponding author on reasonable request. These details do not change the imaging results, but they help define the evidentiary stage of the work: this is an early clinical evaluation showing that the tracer can be used and can generate a strong signal, rather than a definitive comparison with every established imaging option.

The biological logic behind [¹⁸F]SiTATE builds on years of work with SSTR-targeted imaging, including gallium-68-labeled agents and earlier clinical experience with fluorine-18 SiTATE in neuroendocrine tumors. Fluorine-18 production is compatible with widely distributed medical cyclotrons, and the isotope’s physical properties can be advantageous for modern PET systems. Even so, the path from a compelling image to a routine clinical test requires rigorous validation. Prospective studies will need to compare [¹⁸F]SiTATE directly with established gallium-68 tracers and with MRI, ideally while standardizing injected activity, uptake time, scanner technology and interpretation criteria. Researchers will also need to determine how accurately the method identifies atypical or aggressive meningiomas, recurrent disease, postoperative changes and lesions with weaker SSTR2 expression. Reproducibility between hospitals, the effect of lesion size and the clinical value of quantitative parameters such as TLSRE will be equally important.

For now, the study offers a vivid demonstration of how molecular imaging can make a tumor visible not because it changes the anatomy, but because it reveals the receptors displayed by its cells. In 32 of 37 examinations, [¹⁸F]SiTATE turned meningiomas into intensely radioactive landmarks while leaving most normal brain tissue nearly dark. That combination—targeted biology, a comparatively practical fluorine-18 isotope and PET/CT’s ability to unite molecular and anatomical information—could make the tracer an appealing candidate for future meningioma imaging protocols. The researchers conclude that their findings support the feasibility of [¹⁸F]SiTATE and justify prospective comparative evaluation. Until those studies are completed, the tracer remains promising rather than practice-changing. But the images reported in this early cohort point toward a future in which clinicians may be able to see not only where a meningioma is, but also how strongly its cells display a therapeutic and diagnostic molecular target.